ZENTALIS PHARMACEUTICALS INC (ZNTL) Fundamental Analysis & Valuation

NASDAQ:ZNTL • US98943L1070

Current stock price

4.25 USD
+0.27 (+6.78%)
At close:
4.24 USD
-0.01 (-0.24%)
After Hours:

This ZNTL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ZNTL Profitability Analysis

1.1 Basic Checks

  • In the past year ZNTL has reported negative net income.
  • ZNTL had a negative operating cash flow in the past year.
  • ZNTL had negative earnings in each of the past 5 years.
  • ZNTL had a negative operating cash flow in each of the past 5 years.
ZNTL Yearly Net Income VS EBIT VS OCF VS FCFZNTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • ZNTL has a Return On Assets (-47.43%) which is comparable to the rest of the industry.
  • ZNTL has a Return On Equity (-63.39%) which is in line with its industry peers.
Industry RankSector Rank
ROA -47.43%
ROE -63.39%
ROIC N/A
ROA(3y)-46.31%
ROA(5y)-43.55%
ROE(3y)-59.8%
ROE(5y)-55.52%
ROIC(3y)N/A
ROIC(5y)N/A
ZNTL Yearly ROA, ROE, ROICZNTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • ZNTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZNTL Yearly Profit, Operating, Gross MarginsZNTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ZNTL Health Analysis

2.1 Basic Checks

  • ZNTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ZNTL has been reduced compared to 1 year ago.
  • The number of shares outstanding for ZNTL has been increased compared to 5 years ago.
  • There is no outstanding debt for ZNTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZNTL Yearly Shares OutstandingZNTL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ZNTL Yearly Total Debt VS Total AssetsZNTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • ZNTL has an Altman-Z score of -4.19. This is a bad value and indicates that ZNTL is not financially healthy and even has some risk of bankruptcy.
  • ZNTL has a worse Altman-Z score (-4.19) than 60.19% of its industry peers.
  • ZNTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.19
ROIC/WACCN/A
WACC9.41%
ZNTL Yearly LT Debt VS Equity VS FCFZNTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • ZNTL has a Current Ratio of 6.93. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
  • ZNTL has a better Current ratio (6.93) than 66.21% of its industry peers.
  • ZNTL has a Quick Ratio of 6.93. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 6.93, ZNTL is doing good in the industry, outperforming 66.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.93
Quick Ratio 6.93
ZNTL Yearly Current Assets VS Current LiabilitesZNTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ZNTL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.05% over the past year.
  • The Revenue for ZNTL has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.35%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, ZNTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.81% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.52%
EPS Next 2Y3.75%
EPS Next 3Y5.4%
EPS Next 5Y16.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZNTL Yearly Revenue VS EstimatesZNTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
ZNTL Yearly EPS VS EstimatesZNTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. ZNTL Valuation Analysis

4.1 Price/Earnings Ratio

  • ZNTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ZNTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZNTL Price Earnings VS Forward Price EarningsZNTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZNTL Per share dataZNTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.75%
EPS Next 3Y5.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZNTL Dividend Analysis

5.1 Amount

  • No dividends for ZNTL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZNTL Fundamentals: All Metrics, Ratios and Statistics

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (4/27/2026, 5:58:45 PM)

After market: 4.24 -0.01 (-0.24%)

4.25

+0.27 (+6.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)05-12
Inst Owners63.24%
Inst Owner Change-0.11%
Ins Owners2.33%
Ins Owner Change-0.27%
Market Cap301.45M
Revenue(TTM)N/A
Net Income(TTM)-137.06M
Analysts77.33
Price Target5.83 (37.18%)
Short Float %7.78%
Short Ratio2.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.31%
Min EPS beat(2)15.34%
Max EPS beat(2)31.28%
EPS beat(4)4
Avg EPS beat(4)24.53%
Min EPS beat(4)13.92%
Max EPS beat(4)37.6%
EPS beat(8)7
Avg EPS beat(8)28.13%
EPS beat(12)9
Avg EPS beat(12)13.57%
EPS beat(16)11
Avg EPS beat(16)11.29%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.05%
PT rev (3m)7.56%
EPS NQ rev (1m)-2.49%
EPS NQ rev (3m)-14.01%
EPS NY rev (1m)-1.68%
EPS NY rev (3m)-12.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.39
P/tB 1.39
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.94
Fwd EYN/A
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.77
OCFYN/A
SpS0
BVpS3.05
TBVpS3.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -47.43%
ROE -63.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.31%
ROA(5y)-43.55%
ROE(3y)-59.8%
ROE(5y)-55.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.93
Quick Ratio 6.93
Altman-Z -4.19
F-Score3
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)19.71%
Cap/Depr(5y)273.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.35%
EPS Next Y-7.52%
EPS Next 2Y3.75%
EPS Next 3Y5.4%
EPS Next 5Y16.81%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.32%
EBIT Next 3Y1.16%
EBIT Next 5YN/A
FCF growth 1Y26.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.7%
OCF growth 3YN/A
OCF growth 5YN/A

ZENTALIS PHARMACEUTICALS INC / ZNTL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ZNTL.


What is the valuation status for ZNTL stock?

ChartMill assigns a valuation rating of 0 / 10 to ZENTALIS PHARMACEUTICALS INC (ZNTL). This can be considered as Overvalued.


What is the profitability of ZNTL stock?

ZENTALIS PHARMACEUTICALS INC (ZNTL) has a profitability rating of 1 / 10.